PRESS RELEASE published on 06/10/2024 at 08:16, 5 months 12 days ago Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity Biophytis submits IND application to US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone). Study to assess muscle strength & body composition. Research led by Professor Marc-André Cornier Biophytis BIO101 IND Application Obesity Study Professor Marc-André Cornier
PRESS RELEASE published on 06/10/2024 at 08:16, 5 months 12 days ago Biophytis annonce le dépôt d'une demande d'IND auprès de la FDA pour son étude de phase 2 dans l'obésité Biophytis annonce le dépôt d'une demande d'IND auprès de la FDA pour son étude de phase 2 dans l'obésité FDA Biophytis Étude De Phase 2 Obésité Demande D'IND
BRIEF published on 06/07/2024 at 08:28, 5 months 15 days ago Biophytis Announces Combined General Meeting on June 24, 2024 Shareholders Biophytis General Meeting Voting Agenda
BRIEF published on 06/07/2024 at 08:28, 5 months 15 days ago Assemblée générale mixte de Biophytis le 24 juin 2024 Actionnaires Biophytis Biotechnologie Assemblée Générale Vote
REGULATED PRESS RELEASE published on 06/07/2024 at 08:23, 5 months 15 days ago Combined General Meeting of June 24, 2024 Biophytis SA to hold Combined General Meeting (CGM) on June 24, 2024 in Paris. Shareholders encouraged to vote in advance via multiple methods. Details available on the company's website Shareholders Voting Combined General Meeting Biophytis SA CGM
REGULATED PRESS RELEASE published on 06/07/2024 at 08:23, 5 months 15 days ago Assemblée générale mixte du 24 juin 2024 Biophytis SA tiendra son Assemblée Générale Mixte le 24 juin 2024 à Paris. Les actionnaires sont encouragés à voter en amont. La société se concentre sur le développement de traitements pour les maladies liées à l'âge Assemblée Générale Mixte Biophytis SA Vote Actionnaires Traitements Maladies Liées À L'âge Développement Candidats Médicaments
BRIEF published on 06/07/2024 at 07:44, 5 months 15 days ago Assemblée générale mixte de Biophytis prévue le 24 juin 2024 Actionnaires Biophytis Paris Assemblée Générale Vote
BRIEF published on 06/07/2024 at 07:44, 5 months 15 days ago Biophytis Combined General Meeting scheduled for June 24, 2024 Shareholders Biophytis Paris General Assembly Vote
PRESS RELEASE published on 06/07/2024 at 07:39, 5 months 15 days ago Assemblée générale mixte du 24 juin 2024 Biophytis tiendra son Assemblée Générale Mixte le 24 juin 2024 à Paris. Les actionnaires sont invités à voter en amont par différents moyens. Infos sur le site web de la société Actionnaires Biophytis Assemblée Générale Société De Biotechnologie Vote
PRESS RELEASE published on 06/07/2024 at 07:39, 5 months 15 days ago Combined General Meeting of June 24, 2024 Biophytis to hold Combined General Meeting (CGM) on June 24, 2024 at Sorbonne Université. Shareholders urged to vote in advance. Company specializes in age-related disease therapeutics Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
Published on 11/22/2024 at 18:45, 3 hours 28 minutes ago CORRECTING and REPLACING the Not-So-Secret Lives of REAL "Mormon" Wives - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/22/2024 at 16:00, 6 hours 13 minutes ago Manimal Tales Unveils Two New Personalized Christmas-Themed Books to Spread Holiday Magic and Joy!
Published on 11/22/2024 at 15:55, 6 hours 18 minutes ago Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Published on 11/22/2024 at 15:15, 6 hours 58 minutes ago Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 11/22/2024 at 14:45, 7 hours 28 minutes ago Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Published on 11/22/2024 at 18:14, 3 hours 58 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 4 hours 20 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 5 hours 18 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 6 hours 13 minutes ago Proposed cancellation of admission to trading
Published on 11/22/2024 at 16:15, 5 hours 58 minutes ago NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/21/2024 at 06:58, 1 day 15 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
